Clinical Trial

Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2021 (before its estimated September 2023 completion). Its status may not reflect the trial's current state.
Summary
This protocol will evaluate fecal microbiota transplantation (FMT) as a strategy to eradicate intestinal colonization of extended-spectrum resistant (ESC-R) Enterobacteriaceae in pediatric patients. FMT will be performed on subjects with a history of at least one infection due to ESC-R Enterobacteriaceae. This protocol aims to determine the feasibility, safety, tolerability, and potential efficacy of FMT in pediatric patients with a history of ESC-R Enterobacteriaceae.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2015-09-04; most recent amendment 2021-09-22.
Status change: Not Yet Recruiting → Recruiting 2017-04-25
Trial Details
NCT Number NCT02543866
Lead Sponsor Seattle Children's Hospital
Conditions Infection Resistant to Drugs
Enrollment 20 participants
Start Date 2017-02-17
Primary Completion 2023-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2021-09-23